Skip to main content
. Author manuscript; available in PMC: 2015 May 14.
Published in final edited form as: Cell Rep. 2015 Apr 30;11(6):957–966. doi: 10.1016/j.celrep.2015.04.009

Figure 5.

Figure 5

PSM/HER2 DC vaccine inhibited mouse mammary gland tumor growth.

(A) Inhibition of primary TUBO tumor growth. TUBO cells were inoculated into the mammary gland fat pads. After 4 days, mice (n = 8/group) were treated i.v. with PBS, PSM, PSM/p66, DC+p66, or DC+PSM/p66, and tumor growth was monitored in the next 4 weeks. Tumor volume is presented as mean ± SEM.

(B) Tumor multiplicity in Balb-neuT mice with different treatments. The Balb-neuT transgenic mice were divided into 3 groups (n = 5), and treated twice (weeks 6 and 8) i.v. with the indicated agents. Number of tumor nodules per mouse was counted on weekly basis.

(C–E) Quantitative RT-PCR measurement on mRNA levels of IFN-I, pro-inflammatory cytokines, and cytotoxic T cell markers in tumor tissues from different treatment groups.

(F and G) ELISA measurement on intra-tumor cytokine levels in mice with different treatments.

Data are represented as mean ± S.D. except tumor volume. *, P<0.05, **, P<0.01. See also Figure S5.